HEALTH: Strong H2 revenue growth expected, driven by robust pipeline and expanded global partnerships

About this update from Nightingale Health Oyj Class B

Revenue grew 4% in H1, with strong order book and pilots supporting a reiterated 50% full-year growth target. Major partnerships expanded, new contracts secured, and US market entry advanced with the New York lab permit. H2 focus is on targeted sales and commercial scaling.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Nightingale Health Oyj Class B